)
Visual
test
Biotest
Biotest (BIO3) investor relations material
Biotest has been delisted
Biotest Q1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2025 earnings summary12 May, 2025
Executive summary
Q1 2025 revenue fell 42.3% year-over-year to €124.2 million, mainly due to a sharp drop in technology transfer revenue from Grifols and lower product sales.
EBIT declined to €-23.0 million from €52.8 million in Q1 2024, reflecting reduced sales and lower earnings from technology services.
Net loss after taxes was €-21.4 million, compared to a profit of €29.5 million in the prior year period.
Product sales of human albumin and Yimmugo® increased by 17.0% and 10.2% respectively, despite overall product sales decline.
Biotest completed Phase III trials for fibrinogen and advanced regulatory filings in Europe and the US.
Financial highlights
Revenue: €124.2 million (Q1 2025) vs €215.2 million (Q1 2024), down 42.3%.
EBIT: €-23.0 million (Q1 2025) vs €52.8 million (Q1 2024).
Net loss: €-21.4 million (Q1 2025) vs net income €29.5 million (Q1 2024).
EPS: €-0.55 (Q1 2025) vs €0.74 (Q1 2024).
Operating cash flow: €-58.1 million (Q1 2025) vs €-11.6 million (Q1 2024).
Outlook and guidance
2025 sales expected to decline mid single-digit percent from 2024, reflecting lower technology transfer revenue.
EBIT forecasted between €-55.0 million and €-75.0 million for 2025.
ROCE expected between -3% and -7%; operating cash flow anticipated to remain negative.
Risks include Middle East conflict, potential US tariffs on EU pharmaceuticals, and FDA response delays.
Explain the delay of Intratect release.
Assess impact of US tariffs on Biotest.
When is Trimodulin market entry expected?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Biotest
- 2024 sales up 6.1%, EBIT down, delisting offer at €43/ordinary and €30/preference share.BIO3
Q4 202420 Dec 2025 - Revenue up, but earnings down as Biotest shifts focus to core products and R&D.BIO3Q3 202413 Jun 2025
- Strong revenue and profit growth, with US Yimmugo® approval and major licensing boost.BIO3H1 202413 Jun 2025
Biotest
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage